Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Transcutaneous Electrical Nerve Stimulation

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    5 result(s) found for: Transcutaneous Electrical Nerve Stimulation. Displaying page 1 of 1.
    EudraCT Number: 2013-000711-24 Sponsor Protocol Number: 2013-000711-24 Start Date*: 2013-10-09
    Sponsor Name:Søren Rittig
    Full Title: The effect of combining anticholinergic treatment and transcutaneous electrical nerve stimulation in children suffering from daytime urinary incontinence and an overactive bladder.
    Medical condition: Daytime urinary incontinence and overactive bladder
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004857 10059617 Overactive bladder LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-004249-16 Sponsor Protocol Number: F02207GE204 Start Date*: 2005-02-02
    Sponsor Name:PIERRE FABRE MEDICAMENT
    Full Title: THE EFFECT OF MILNACIPRAN 100MG BID ON SENSITIVITY TO STIMULUS-EVOKED PAIN IN PATIENTS WITH FIBROMYALGIA: A FMRI NEUROIMAGING STUDY
    Medical condition: Fibromyalgia is a chronic disorder characterized by widespread musculoskeletal pain, widespread tenderness and fatigue. The disorder is well defined in the USA, where the current diagnosis of FMS i...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed) SE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-003137-40 Sponsor Protocol Number: F02207GE302 Start Date*: 2015-09-28
    Sponsor Name:Pierre Fabre Medicament
    Full Title: A European Phase III, Multicentre, Double-blind, Randomised, Placebo-Controlled Monotherapy Study of Milnacipran for the Treatment of the Fibromyalgia Syndrome.
    Medical condition: Fibromyalgia, also known as FMS, is a common systemic rheumatologic disorder estimated to affect 2 to 4% of the population Fibromyalgia is associated with a reduced threshold for pain, generally i...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) FI (Completed) SE (Completed) ES (Completed) PT (Completed) DE (Completed) GB (Completed) CZ (Completed) IT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-001175-32 Sponsor Protocol Number: BIA-91067-404 Start Date*: 2020-09-29
    Sponsor Name:Bial - Portela & Ca, S.A.
    Full Title: Randomised, double-blind, placebo-controlled, clinical study to evaluate the effect of opicapone 50 mg on Parkinson’s disease patients with end-of-dose motor fluctuations and associated pain.
    Medical condition: Parkinson's disease patients with wearing-off motor fluctuations and associated pain.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) PT (Completed) IT (Ongoing) CZ (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005061-20 Sponsor Protocol Number: ONU3705 Start Date*: 2012-06-19
    Sponsor Name:Purdue Pharma L.P.
    Full Title: A Randomized, Double-blind, Double-dummy, Placebo-controlled, Active-controlled, Parallel-group, Multicenter Trial of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess the Analgesic Eff...
    Medical condition: Opioid-induced Constipation & Moderate to Severe Chronic Low back Pain
    Disease: Version SOC Term Classification Code Term Level
    14.1 10017947 - Gastrointestinal disorders 10071128 Opioid induced constipation LLT
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10003988 Back pain PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) PL (Completed) SK (Completed) DK (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 03:35:34 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA